Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03740165IIINewly diagnosed stage III/IV ovarian cancer without BRCA1/2 mutationsA Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)AL, AZ, CA, CT, FL, GA, IL, IN, IA, KY, MD, MS, MO, NE, NH, NJ, NY, ND, OH, RI, SD, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04095364IIINewly diagnosed stage II-IV low grade serous ovarian cancer that is TP53 WTA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumAK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04498117IIINewly diagnosed BRCA WT and HRD- stage III/IV ovarian cancer following optimal cytoreduction at primary or interval surgeryA Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaAZ, CA, CT, FL, GA, LA, MA, MN, NJ, NY, NC, OH, OK, PA, RI, SD, TN, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
OregovomabOvaRex, Monoclonal Antibody B43.13, B43.13Immune response against cancer expressing CA125Clinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02834975IINewly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant ChemotherapyFLView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03531645IINewly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)Approved in Other Cancers
NCT04606914IINewly diagnosed stage III-IV high grade serous FRalpha+ ovarian cancer (neoadjuvant)Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α PositiveALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT02033616IINewly diagnosed stage III/IV ovarian cancer or stage III/IV ovarian cancer after completion of first-line therapyPhase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary TherapyCA, COView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AVOVA-1TAA-loaded autologous dendritic cell vaccine, Autologous Dendritic Cells Loaded With Autologous Tumor Associated AntigensImmune response against tumor-associated antigensClinical Trials
NCT02122185IINewly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal CancerAL, CA, IL, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
MetforminFortamet, Glucophage, Glumetza, RiometAMP-activated protein kinase (AMPK) activatorApproved in Other Indications
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04082572IINewly diagnosed advanced solid tumors with dMMR or high MSINeoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid CancersTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryOKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GalunisertibLY2157299TGFBR1 antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03206645IbNewly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer CellsOKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PTC596BMI1 inhibitor PTC596, polycomb ring finger oncogene inhibitor PTC596BMI1 inhibitorClinical Trials
NCT03393884I/IINewly diagnosed stage III/IV ovarian cancer (neo-adjuvant)A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerAL, CA, FL, MA, MO, MT, NJ, NY, OK, PA, SD, TN, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GEN-1PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPCIL-12 receptor agonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03245892INewly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant)A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04598321INewly diagnosed stage II-IV, BRCA MUT, mixed epithelial carcinoma, high grade serous or endometrioid ovarian cancer (neo-adjuvant)BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)RIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT03607955INewly diagnosed stage III/IV ovarian cancer (neo-adjuvant)Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyMO, OKView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AVB-S6-500AVB-500GAS6 antagonistClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04367675IOvarian cancer with no evidence of disease after first-line treatmentPhase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 MutationsContact research study staffView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INO-5401WT1/PSMA/hTERT-encoding plasmid DNA INO-5401Immune response against cancer expressing hTERT, PMSA or WT1Clinical Trials
INO-9012DNA plasmid encoding interleukin-12 INO-9012IL-12 receptor agonistClinical Trials
NCT04024878INewly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence)NeoVax With Nivolumab in Patients With Ovarian CancerMAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NeoVaxImmune response against tumor-associated antigensClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03839524IHigh grade serous ovarian cancer with complete response after first-line platinum therapy (w/ banked tumor tissue)A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.AZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TG4050MyVAC, Modified Vaccinia Ankara (MVA) personalized vaccineImmune response against tumor-associated antigensClinical Trials
NCT02659241INewly diagnosed high grade serous ovarian cancerA Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian CancerTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitorClinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.